Metformin in polycystic ovary syndrome

@article{DiamantiKandarakis2010MetforminIP,
  title={Metformin in polycystic ovary syndrome},
  author={Evanthia Diamanti-Kandarakis and Frangiskos N Economou and Sotiria Palimeri and Charikleia D Christakou},
  journal={Annals of the New York Academy of Sciences},
  year={2010},
  volume={1205}
}
Polycystic ovary syndrome (PCOS) affects 6.6–6.8% of women in reproductive age. Insulin resistance and hyperinsulinemia play a critical role in the pathogenesis of PCOS and are associated with a high risk for type 2 diabetes mellitus and cardiometabolic abnormalities. Metformin has been introduced as a therapeutic option in PCOS, targeting of cardiometabolic and reproductive abnormalities on the basis of its action on the reduction of glucose levels and the attenuation of insulin resistance… 

Advances in Treatment Options for Polycystic Ovary Syndrome

An increasing level of therapeutic sophistication is reflected in ovarian stimulation protocols judiciously using gonadotropins, gonadotropic-releasing hormone antagonists, the procedure of ovarian drilling, and assisted reproductive technologies with in vitro oocyte maturation.

Polycystic Ovarian Syndrome and Response to Stimulation

Polycystic ovary syndrome is one of the most common endocrine disorders affecting females and various regimens have been developed for the treatment ranging from lifestyle modification to clomiphene to IVF with no consensus.

COMPLICATIONS OF PREGNANCY IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME

The manifestation of PCOS and its impact especially on reproductive function and pregnancy are profoundly affected by associated features of obesity/raised body mass index and metabolic syndrome.

Combination of Melatonin and Metformin Hydrochloride for Treatment Polycystic Ovarian in Female Rats

The treatment with a combination of metformin hydrochloride and melatonin was more effective against hormonal alterations produced by PCOS, allowing a normalization of biochemical parameters during pregnancy, than monotherapeutic treatment with these drugs.

Polycystic ovary syndrome - Effect of acupuncture on insulin resistance and neuroendocrine function

As shown in this thesis, acupuncture treatment elicits local and systemic effects which have the capacity to break the vicious circle of androgen excess, ovarian dysfunction and possibly reduced insulin sensitivity in PCOS.

Reproductive endocrinology: Metformin or thiazolidinedione therapy in PCOS?

Insulin resistance has a key role in the pathogenesis of polycystic ovary syndrome, a common endocrinopathy that affects young women. Therefore, the use of insulin-sensitizing agents has been studied

Metformin reduces hyper-reactivity of platelets from patients with polycystic ovary syndrome by improving mitochondrial integrity.

The improvement of mitochondrial integrity and platelet reactivity may contribute to the beneficial effects of metformin on cardiovascular disease.

Circulating Microparticles as Indicators of Cardiometabolic Risk in PCOS.

The impact of obesity and fitness on endothelial function in polycystic ovarian syndrome

The primary aim of this thesis was to examine nitric oxide (NO)-mediated endothelial function at different levels of the vascular tree in women with PCOS and to establish whether supervised exercise training induces a therapeutic effect on endothelialfunction.

Metformin increases norepinephrine transporter expression in placenta of patients with polycystic ovary syndrome.

Remarkably, metformin administration during pregnancy decreases circulating norepinephrine levels and increases NET expression in the maternal side of placentas from PCOS women.
...

References

SHOWING 1-10 OF 42 REFERENCES

Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.

The uses of metformin are analyzed not only for the treatment of all PCOS-related disturbances such as menstrual disorders, anovulatory infertility, increased abortion, or complicated pregnancy risk, hyperandrogenism, endometrial, metabolic and cardiovascular abnormalities, but also for the prevention of the syndrome.

Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.

This review attempts to cover the spectrum of metformin's cellular actions in different tissues and to summarize the current literature regarding the potential medical value of this medication in PCOS.

Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.

Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses, and additional studies are required to determine whether other aspects of the disorder may benefit from the higher dose of meetformin.

Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene.

It is demonstrated that a polymorphism in STK11, a kinase gene expressed in liver and implicated in meetformin action, is associated with ovulatory response to treatment with metformin alone in a prospective randomized trial.

Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications

The molecular mechanisms known to underlie the ovarian and metabolic abnormalities characterising PCOS are reviewed, and the putative interdependence between reproductive and metabolic aspects of PCOS, and therapeutic implications for the management of the syndrome are discussed.

A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

Polycystic ovary syndrome appears to be a particularly common endocrine disorder in the Greek population under study and it is associated with certain metabolic abnormalities, suggesting that the severity of the fasting hyperinsulinemia isassociated with the severity with the clinical phenotype of hyperandrogenism independently of obesity.

Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.

Metformin does not improve weight loss or menstrual frequency in obese patients with PCOS, and weight loss alone through lifestyle changes improves menstrual frequency.